EMA to streamline bioequivalence testing for specific generic substances
This article was originally published in SRA
Companies planning generic drug submissions in the EU are to have new guidance on how to demonstrate the bioequivalence of specific active substances, in an effort to make bioequivalence assessment more transparent and predictable.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.